Latest Breaking News On - அரவிந்தோ பார்மா ஒன்றுபட்டது மாநிலங்களில் இன்க் - Page 1 : comparemela.com

Health your username May 10, 2021 Amgen Inc. and its subsidiary KAI Pharmaceuticals Inc. filed a complaint in the District of Delaware last week against Aurobindo Pharma Limited and Aurobindo Pharma USA Inc. (collectively, Aurobindo), alleging that Aurobindo infringed their patents by filing for a generic version of the drug Parsabiv. According to the complaint, Aurobindo filed Abbreviated New Drug Application (ANDA) No. 215840 to the U.S. Food and Drug Administration (FDA) “seeking approval to manufacture and sell a generic version of Parsabiv® (etelcalcetide) injection for intravenous use at strengths of 2.5mg/0.5mL, 5mg/mL, and 10mg/2mL (‘Aurobindo’s Proposed ANDA Product’)” before the plaintiffs’ patents – U.S. Patent Nos. 9,820,938 and 10,344,765 – expire. The plaintiffs stated that they were notified by Aurobindo in a letter that they received in March 2021 that it submitted the ANDA. The plaintiffs alleged that based on information and belief, Aurobindo’

United statesLatham watkinsDrug administrationAurobindo pharma united states incAmgen incAurobindo pharmaPharmaceuticals incAurobindo pharma limitedAurobindo pharma united statesAbbreviated new drug applicationNew drug applicationஒன்றுபட்டது மாநிலங்களில்லாதம் வாட்கின்ஸ்அரவிந்தோ பார்மா ஒன்றுபட்டது மாநிலங்களில் இன்க்மகேன் இன்க்அரவிந்தோ பார்மா